Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens

NCT02864368 is registered in ClinicalTrials.gov with Eric Thompson, M.D. as lead sponsor.

NCT NCT02864368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02864368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Lead sponsor
Eric Thompson, M.D.
Phase
Phase 1
Overall status
Terminated
Start date
December 7, 2016
Completion date
June 15, 2020
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioblastoma multiforme